Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

By LabMedica International staff writers
Posted on 14 Apr 2025

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. More...

The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies on subjective assessments and expensive or invasive procedures, such as amyloid positron emission tomography (PET) scans and cerebrospinal fluid (CSF) tests. Consequently, many patients are not diagnosed until the disease has progressed significantly, reducing the efficacy of available treatments. Now, a breakthrough has made it possible to detect Alzheimer’s through a simple blood test.

A collaborative study, led by researchers from the Hospital del Mar Research Institute (IMIM, Barcelona, Spain), has successfully demonstrated the potential for determining the risk of Alzheimer’s in individuals showing signs of cognitive impairment by detecting a biomarker called phospho-tau217 in their blood. Published in Nature Medicine, this study validated the Lumipulse p-tau217, an automated and scalable blood test system developed by Fujirebio (Tokyo, Japan), which accurately identifies the threshold levels indicating whether a person is at risk of developing the disease or is free from that risk. The research team analyzed data from four hospital-based cohorts and one primary care cohort, involving a total of 1,767 individuals. Previous studies by this group had already confirmed that the biomarker could identify Alzheimer’s risk during its preclinical stages.

The study found that the automated blood test accurately predicted Alzheimer’s risk with over 90% accuracy in hospital patients, a result comparable to that of a lumbar puncture. The researchers took into account patient factors such as comorbidities (like diabetes and kidney function) and age. However, the accuracy was lower in primary care patients and those older than 80 years. The new diagnostic tool has the potential to significantly cut down the costs of diagnosing Alzheimer’s, with savings estimated between 60% and 81% compared to current diagnostic tests. This economic advantage, combined with its large-scale applicability, could greatly improve access to early diagnosis and the clinical management of Alzheimer’s disease. Nonetheless, the researchers emphasize that additional studies are necessary before the test can be fully integrated into clinical practice.

“This development may allow us to determine who needs to undergo further tests, such as a lumbar puncture or a PET scan, and who doesn’t, as it enables the detection of Alzheimer’s in its early stages with great accuracy,” said Dr. Marc Suárez-Calvet, a neurologist at Hospital del Mar and researcher at its research institute and the Barcelonaβeta Brain Research Center. “We have been able to establish two cut-off points that help us determine this risk. People whose p-tau217 biomarker levels fall between these two thresholds are the ones who need further testing.”


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.